Compare Stocks → The Gold Grab of the Century (From Colonial Metals) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BPTHNASDAQ:NVUSNASDAQ:RTTRNASDAQ:TLGTNASDAQ:VVUS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPTHBio-Path$2.68+1.9%$4.77$2.35▼$44.80$1.82M0.351.11 million shs117,120 shsNVUSNovus Therapeutics$2.06+2.0%$13.23$4.50▼$27.32$2.96M2.0778,851 shs81,544 shsRTTRRitter Pharmaceuticals$0.30-3.3%$2.99$0.15▼$1.27$13.71M-0.4314.23 million shs17,611 shsTLGTTeligent$0.03$0.17▼$1.60N/AN/AN/A6,460 shsVVUSVIVUS$0.37$0.44▼$4.75$7.33M-0.841.44 million shs2.03 million shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPTHBio-Path+5.82%-37.26%-34.45%-71.96%-89.20%NVUSNovus Therapeutics0.00%+25.48%-7.08%+8.24%-12.05%RTTRRitter Pharmaceuticals-3.85%-4.72%-25.94%-41.20%-66.63%TLGTTeligent0.00%0.00%0.00%0.00%0.00%VVUSVIVUS0.00%0.00%0.00%0.00%0.00%These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPTHBio-Path2.5016 of 5 stars3.55.00.00.02.40.00.6NVUSNovus TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARTTRRitter PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/AN/AN/AN/AVVUSVIVUSN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPTHBio-Path3.00Buy$40.001,392.54% UpsideNVUSNovus TherapeuticsN/AN/AN/AN/ARTTRRitter PharmaceuticalsN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AVVUSVIVUSN/AN/AN/AN/ACurrent Analyst RatingsLatest VVUS, NVUS, RTTR, BPTH, and TLGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.003/27/2024BPTHBio-PathRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $40.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPTHBio-PathN/AN/AN/AN/A$0.71 per shareN/ANVUSNovus TherapeuticsN/AN/AN/AN/A$13.13 per shareN/ARTTRRitter PharmaceuticalsN/AN/AN/AN/A$0.10 per shareN/ATLGTTeligentN/AN/AN/AN/AN/AN/AVVUSVIVUS$69.76M0.00N/AN/A($6.50) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPTHBio-Path-$16.08M-$40.80N/AN/AN/AN/A-375.74%-248.63%5/10/2024 (Estimated)NVUSNovus Therapeutics-$16.01M-$21.58N/AN/AN/AN/A-133.49%-30.52%N/ARTTRRitter Pharmaceuticals-$10.13MN/AN/A∞N/AN/AN/A-162.05%N/ATLGTTeligentN/AN/A0.00N/AN/AN/AN/AN/AN/AVVUSVIVUS-$31.50M-$2.96N/AN/AN/A-39.28%N/A-12.18%N/ALatest VVUS, NVUS, RTTR, BPTH, and TLGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/8/202412/31/2023BPTHBio-Path-$5.40-$5.40N/AN/AN/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPTHBio-PathN/AN/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/AN/ARTTRRitter PharmaceuticalsN/AN/AN/AN/AN/ATLGTTeligentN/AN/AN/AN/AN/AVVUSVIVUSN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPTHBio-PathN/A1.601.60NVUSNovus TherapeuticsN/A18.7818.78RTTRRitter PharmaceuticalsN/A3.673.67TLGTTeligentN/AN/AN/AVVUSVIVUSN/A0.430.28OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPTHBio-Path5.74%NVUSNovus TherapeuticsN/ARTTRRitter Pharmaceuticals0.84%TLGTTeligentN/AVVUSVIVUS7.32%Insider OwnershipCompanyInsider OwnershipBPTHBio-Path3.05%NVUSNovus Therapeutics2.20%RTTRRitter Pharmaceuticals15.40%TLGTTeligent0.17%VVUSVIVUS12.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBPTHBio-Path10680,000658,000OptionableNVUSNovus Therapeutics71.44 millionN/ANot OptionableRTTRRitter Pharmaceuticals746.15 millionN/ANot OptionableTLGTTeligent2,357N/AN/AOptionableVVUSVIVUS5717.87 millionN/AOptionableVVUS, NVUS, RTTR, BPTH, and TLGT HeadlinesSourceHeadlineVIVUS Provides Update on Pipeline and Program Milestonesmarkets.businessinsider.com - January 8 at 10:04 AMShark research group to build new global headquarters in Jacksonville with help from state fundingactionnewsjax.com - June 26 at 9:16 AMMetaview announces Answers, the world's first conversational AI for the interview processit.tmcnet.com - May 25 at 11:10 AMPancrelipase (CAS 53608-75-6) Market 2023 | Industry Growth ... - StreetBuzznews.google.com - May 12 at 2:58 AMExploring Huge Demand of Peripherally Acting Anti-Obesity Drug ... - Digital Journalnews.google.com - May 12 at 2:58 AMExtensive Growth Opportunities to be Witnessed by Prescription Weight-Loss Pills Market 2023 Analysis of Risin - openPRnews.google.com - May 11 at 8:54 AMErectile Dysfunction Drugs Market to Register High Demand Rate by ... - Cottonwood Holladay Journalnews.google.com - May 11 at 8:54 AMMilestone Pharmaceuticals Reports First Quarter 2023 Financial ... - PR Newswirenews.google.com - May 11 at 8:54 AMAnti-obesity Therapeutics Market to Witness the Highest Growth ... - Cottonwood Holladay Journalnews.google.com - May 11 at 3:54 AMAnti Obesity Drugs Market Future Industry Scope for New ... - Digital Journalnews.google.com - May 11 at 3:54 AMThis Crazy Six-Wheel Hatchback by Briggs & Stratton Was One of ... - autoevolutionnews.google.com - May 10 at 12:51 PMProstatic Artery Embolization Market Current and Upcoming Projects ... - Digital Journalnews.google.com - May 9 at 6:48 AMThis 1899 Porsche Pioneered Rivian's Quad-Motor Drive, Ram ... - MotorBiscuitnews.google.com - May 7 at 8:20 PMPorsche Pioneered the Range-Extended EV 100+ Years Before ... - MotorBiscuitnews.google.com - May 6 at 3:22 PMIncreasing Opportunities In Peripherally Acting Anti-Obesity Drug Market Latest Trends, Technological Advancem - openPRnews.google.com - May 5 at 1:45 PMNonalcoholic Steatohepatitis Treatment Market Outlook Growths ... - Digital Journalnews.google.com - May 5 at 7:44 AMA Big Fat Problem: Will children in the UK be given weight-loss injections? - Firstpostnews.google.com - May 2 at 10:24 AMIntraoperative Ultrasound Market Latest Trends, Techniques and Applications|2023-2030 - openPRnews.google.com - April 28 at 9:38 AMBuild Your Own Case Study | Obesity: Treating the Whole Patient - Healionews.google.com - April 27 at 8:14 PMBladder Cancer Market Demand in Various industries and Significant for Various Regions|2023-2030 - openPRnews.google.com - April 27 at 3:10 PMPediatric Obesity Management Market is projected to grow with a 4 ... - Future Market Insightsnews.google.com - April 27 at 10:10 AMGlobal Erectile Dysfunction Drugs Market Analysis by Recent Trends, Development, Regional Growth Overview and - openPRnews.google.com - April 26 at 7:33 AMNon-Alcoholic Steatohepatitis (NASH) Market Analysis, Trends, Growth, Research And Forecast 2032 - openPRnews.google.com - April 25 at 2:02 AMWhat to Know About Obesity and Bone Health - Health Centralnews.google.com - April 24 at 4:02 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBio-PathNASDAQ:BPTHBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.Novus TherapeuticsNASDAQ:NVUSNovus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.Ritter PharmaceuticalsNASDAQ:RTTRRitter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.TeligentNASDAQ:TLGTTeligent, Inc. engages in the development, manufacture, and market of topical and branded generic and generic injectable pharmaceutical products. It also provides contract manufacturing services to the pharmaceutical, over-the-counter, and cosmetic markets. The company was founded by Jane E. Hager in 1977 and is headquartered in Buena, NJ.VIVUSNASDAQ:VVUSVIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.